Top 100 biotech venture investors; Bristol Myers’ IL-12 breakup; Scientific twist of fate; Tracking biopharma layoffs; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
Thanks for reading. This week is extra special — and not just because of the Super Bowl — as it marks the 100th edition of the Endpoints Weekly. I’d love to hear from you on what you like about this report — and what you think could be better. You can always reply to this email to get in touch. (Correction note: In last week’s email, I mistakenly wrote that Bristol Myers Squibb abandoned two “peptide-masked” CTLA-4 programs. Only one of the two discontinued CTLA-4 programs was peptide-masked.)
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.